Company presentation

BW Offshore is presenting today at Pareto Securities’ annual Energy Conference. Please see the attached presentation.

For further information, please contact:
Ståle Andreassen, CFO, +47 91 71 86 55
IR@bwoffshore.com   www.bwoffshore.com

About BW Offshore:

BW Offshore engineers innovative floating production solutions. The Company has a fleet of FPSOs and floating wind solutions. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets worldwide. BW Offshore has around 900 employees and is publicly listed on the Oslo stock exchange.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachment

Press Release
Data on Nicox’s NCX 470 to be presented at AAOpt Annual Meeting 2026
September 16, 2026 – release at 7:30 am
Sophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that key scientific data on NCX 470 will be presented at the upcoming American Academy of Optometry (AAOpt) Annual Meeting 2026 (September 30 – October 3, 2026, Anaheim, CA, U.S.). Nicox will also be participating in several key ophthalmology, financial and industry conferences in the second half of 2026.

“NCX 470 is an investigational new drug for the reduction of intraocular pressure which has recently completed a multi-region Phase 3 clinical program. AAOpt provides an important opportunity to share the data from these trials directly with the optometrist community, which plays a central role in the diagnosis and ongoing management of glaucoma. This forum enables us to engage directly with optometrists and place the clinical findings for NCX 470 in the context of glaucoma management in everyday practice.” said Siobhan Garbutt, VP and Head of Clinical Development of Nicox.

Data from Nicox’s clinical trials, Denali, Whistler and Mont Blanc has already been presented at a number of key ophthalmology conferences. All publications can be found on our website.

AAOpt 2026 Annual Meeting – September 30 to October 3, 2026, Anaheim, CA, U.S. 

Presentation Details

 

Title: The Denali Trial U.S. Subgroup: A Randomized Trial Comparing NCX 470 0.1% and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension
Type: Paper Presentation
Date: Thursday, October 1, 2026 at 08:15 am (local time)
Presenter: Nora Cothran, OD, Fellow of the American Academy of Optometry

Title: Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (Nitric Oxide-Donating Bimatoprost): A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial

Type: Poster Presentation – Board #162
Date: Thursday, October 1, 2026 at 4:30 pm (local time)
Presenter: Siobhan Garbutt, PhD

H2 Conference Attendance

  • American Academy of Ophthalmology (AAO) – October 9-12, 2026 – New Orleans, Louisiana – United-States
  • Investor Access – October 6-7, 2026 – Paris, France

Members of the Nicox team will be available for one-on-one meetings at these events. If you wish to set up a meeting, please contact us at communications@nicox.com.

About NCX 470
NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signalling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs.

NCX 470 has completed two Phase 3 clinical trials designed to fulfil the regulatory requirements for safety and efficacy to support NDA submissions in the U.S. and China, Mont Blanc and Denali. Both trials were positive and met the efficacy endpoints necessary for submission of a New Drug Application in the United States and China. NDAs for NCX 470 have been submitted in the U.S. and China. NCX 470 is an investigational product and has not yet been approved by the FDA.

About Nicox
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world.  Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos.  Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories.  Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX).

For more information www.nicox.com

Analyst coverage

H.C. Wainwright & Co        Yi Chen           New York, U.S.

 
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts  
Nicox
Gavin Spencer
Chief Executive Officer
T +33 (0)4 97 24 53 00
communications@nicox.com
 
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” and in section 4 of the “Rapport semestriel 2025” which are available on Nicox’s website (www.nicox.com).

Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

Nicox S.A.
Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France
T +33 (0)4 97 24 53 00

Attachment

EfTEN United Property Fund earned a net profit of 58 thousand euros in August and 624 thousand euros over the first eight months of 2026 (2 012 thousand euros in the same period last year). The net asset value (NAV) of the fund unit was 11.58 euros at the end of August, increasing 0.2% over the month.

The lower-than-usual profit was primarily related to the fund’s investment in the shares of EfTEN Real Estate Fund AS, the price of which fell by 1.8% on the Tallinn Stock Exchange in August 2026. If the fund’s investment in the shares of EfTEN Real Estate Fund AS were recognised on the basis of its net asset value, EfTEN United Property Fund would have earned 163 thousand euros of profit in August and the fund’s NAV would be 11.66 euros, increasing 0.6% over the month.

In August, the fund acquired a 5.9% holding in EfTEN Domina SIA, which owns the Domina shopping centre in Riga. The acquisition cost of the fund’s investment was 2,478 thousand euros, and in August the fund earned 31 thousand euros of profit from the change in the fair value of the holding.

In August, the fund also acquired an 80% holding in its subsidiary Invego Uus-Järveküla 2 OÜ, which is developing the expansion of the Uus-Järveküla residential district. The detailed plan for the expansion is in its final phase. The fund earns 10% annual interest income on the 700 thousand euro shareholder loan granted to the company at the end of July.

No new sales agreements were concluded in August in the development company Invego Uus-Järveküla OÜ, in which the fund holds an 80% stake. Three terraced-houses and two land plots remain unsold in the development project.

A more detailed overview of EfTEN United Property Fund’s portfolio can be found on the fund’s website: https://eftenunitedpropertyfund.ee/en/fund-results-2/

Kristjan Tamla
Managing Director
Phone: 655 9515

E-mail: kristjan.tamla@eften.ee

Attachment

VALLOUREC SECURES A MAJOR CONTRACT WITH SUBSEA7 FOR PETROBRAS’ SEPIA 2 OFFSHORE PROJECT IN BRAZIL

Meudon, on September 16, 2026 – Vallourec, a world leader in premium seamless tubular solutions, announces that it has been awarded a major contract by Subsea7 for the supply of carbon steel seamless line pipe and thermal insulation coating for the Sepia 2 project, developed by Petrobras in the pre-salt Santos Basin, offshore Brazil.

This award follows the EPCI (Engineering, Procurement, Construction and Installation) contract recently secured by Subsea7 from Petrobras for the Sepia 2 project. Vallourec has secured the project’s entire carbon steel line pipe and external coating supply scope through a single integrated offer.

Under this contract, Vallourec will supply approximately 130 kilometers of rigid risers and flowlines, representing more than 15,000 tons of sour service carbon steel line pipe. The pipes will be produced at Vallourec’s Jeceaba mill in Minas Gerais, Brazil, with the related thermal insulation coating applied at the Vallourec Coating Solutions plant in Serra, Espírito Santo.

The Sepia 2 project is located in ultra-deep waters of the Santos Basin, a pre-salt area approximately 280 kilometers from the Brazilian coast, and is developed by a consortium led by Petrobras. It comprises 15 wells, as well as an export pipeline connected to a new
Floating Production Storage and Offloading (FPSO) vessel, to be installed in a water depth of approximately 2,170 meters.

This success highlights Vallourec’s ability to meet the highly demanding thermal insulation requirements of the installation and operation phases in extreme deepwater conditions. Thanks to its advanced Syntactic Polypropylene solutions, Vallourec will stand alongside Subsea7 and Petrobras to meet these challenges throughout project execution.

Philippe Guillemot, Chairman of the Board of Directors and Chief Executive Officer of the Vallourec Group, commented: “This contract illustrates the strength of Vallourec’s integrated offering, combining premium seamless line pipe and advanced thermal insulation coating. It confirms our position as a partner of choice for the most demanding pre-salt developments and showcases the excellence of our fully integrated industrial footprint in Brazil, from our Jeceaba mill to our Serra coating plant. I thank Subsea7 and Petrobras for this new mark of confidence, which rewards the dedication of our teams.”

About Vallourec

Vallourec is a world leader in premium tubular solutions for the energy markets and for demanding industrial applications such as oil & gas wells in harsh environments, new generation power plants, challenging architectural projects, and high-performance mechanical equipment. Vallourec’s pioneering spirit and cutting-edge R&D open new technological frontiers. With close to 13,000 dedicated and passionate employees in more than 20 countries, Vallourec works hand- in-hand with its customers to offer more than just tubes: Vallourec delivers innovative, safe, competitive and smart tubular solutions, to make every project possible. Listed on Euronext in Paris (ISIN code: FR0013506730, Ticker VK), Vallourec is part of the CAC Mid 60, SBF 120 and Next 150 indices and is eligible for Deferred Settlement Service. In the United States, Vallourec has established a sponsored Level 1 American Depositary Receipt (ADR) program (ISIN code: US92023R4074, Ticker: VLOWY). Parity between ADR and a Vallourec ordinary share has been set at 5:1. 

For further information, please contact:

Investor relations:

Daniel Thomson
Tel: +44(0)75 91 83 74 05
daniel.thomson@vallourec.com

Individual shareholders:
Toll Free number (From France): 0 805 65 10 10 
actionnaires@vallourec.com

Press relations: Taddeo

Romain Grière
Tel: +33 (0) 7 86 53 17 29
Tel: + 1 718 421 8374
romain.griere@taddeo.fr

Nicolas Escoulan
Tel: +33 (0)6 42 19 14 74
nicolas.escoulan@taddeo.fr

Attachment

The Management Board of TextMagic AS (registry code: 16211377, hereinafter the Company) proposes this draft resolution of the shareholders with a view to adopting, without calling a meeting in accordance with Section 2991 of the Commercial Code, the resolution of the shareholders of the Company on approval of the decrease of the voluntary reserve capital. 

In order to optimize costs, the Management Board of the Company has decided to arrange for the resolution to be adopted without convening a meeting and hence not to organise a general meeting of shareholders. 

Draft resolution:

Reduction of the voluntary reserve capital

Proposal of the Supervisory Board and the Management Board, and draft resolution.

1. To reduce the voluntary reserve capital of the Company by EUR 1,722,000 and to make a distribution to the shareholders in accordance with this resolution.

2. The distribution to be made as a result of the reduction of the Company’s voluntary reserve capital shall amount to EUR 0.20 per share (EUR 1,722,000 in total).

3. The remaining balance of the voluntary reserve capital after the distribution shall be EUR 25,988,000.

4. The distribution shall be allocated among all shareholders in proportion to the number of shares held by each shareholder in accordance with clause 4.12 of the Company’s articles of association.

The list of shareholders entitled to receive the distribution resulting from the reduction of the voluntary reserve capital shall be determined as at the close of the business day on 08.10.2026 (record date) in the Nasdaq CSD Estonian settlement system. Accordingly, the ex-date for the change of rights attached to the shares shall be 07.10.2026. The distribution shall be made to the shareholders no later than 14.10.2026.

Procedure and instructions for voting

A shareholder may review all documents related to the draft resolution on Company’s investors’ website https://investor.textmagic.com/ and at the Company’s location at A. H. Tammsaare tee 56, Tallinn, Harju County during business days from 09:00 to 17:00.

Questions regarding draft resolution, voting and other organizational issues are to be submitted to the Company’s e-mail address investor@textmagic.biz no later than by 25.09.2026 at 17:00.

The list of shareholders entitled to vote is fixed seven days before the end of the voting, i.e., on 23.09.2026 at the end of the business day of the settlement system of Nasdaq CSD Estonia. Shareholders may vote on draft resolutions only either by electronic means or by submitting a paper vote as follows:

  1. the voting will be open from 10:00 on 16.09.2026 until 12:00 on 30.09.2026 (GMT +3);
  2. a blank voting ballot is available at https://investor.textmagic.com/ where it can be filled in and the completed document can be downloaded for signing;
  3. for electronic voting, a shareholder or its representative must fill in a blank voting ballot in accordance with the instructions therein, sign it electronically (using an ID card, digital ID or Mobile ID) and forward the electronically signed voting ballot to the e-mail address investor@textmagic.biz by the deadline specified in clause (i) above;
  4. for paper voting, a shareholder or its legal or authorized representative must fill in a blank voting ballot in accordance with the instructions therein, sign it on paper and send the scanned voting ballot to the e-mail address investor@textmagic.biz and the original voting ballot to the Company’s head office at A. H. Tammsaare tee 56, 11316 Tallinn, Harju County, so that it arrives no later than at 12:00 (GMT+3) on 30.09.2026;
  5. if a blank voting ballot is filled in by an authorized representative of a shareholder, the original of the relevant power of attorney in the form (in electronic form or on paper) and by the time specified in (iv) above must be delivered in addition to the voting ballot itself. A template of the power of attorney is available at https://investor.textmagic.com/;
  6. if a blank voting ballot is filled in by a foreign legal entity, an extract of the registration entry of the relevant foreign legal entity, in the form (in electronic form or on paper) and by the time specified in (iv) above, showing the persons entitled to represent the foreign legal person must be delivered in addition to the voting ballot itself (and the power of attorney, if applicable).

Pursuant to Section 2991(2) of the Commercial Code, if a shareholder does not state within the specified term whether the shareholder is for or against a resolution, the shareholder will be deemed to have voted against the resolution.

The Management Board will publish the voting results as a stock exchange announcement and on the Company’s website in accordance with Section 2991(6) of the Commercial Code.
 

The following annexes are attached to this draft resolution:

Annex 1 – a blank voting ballot 
Annex 2 – a template of power of attorney

For more information, please contact:

Priit Vaikmaa
TextMagic AS CEO
investor@textmagic.biz

Attachments

TGS’ presentation for the Pareto Securities Energy Conference 2026 can be downloaded from www.newsweb.no or TGS’ website www.tgs.com.

CEO Kristian Johansen will present today at 15:55 CEST.

For more information, visit TGS.com (http://www.tgs.com) or contact:

Bård Stenberg VP IR & Business Intelligence

Mobile: +47 992 45 235 investor@tgs.com

Attachment

Strategic shareholders commit A$7.1 million at a premium to market, the Company’s fourth consecutive equity raise priced at a premium, alongside A$3.75 million of non-dilutive R&D Tax Incentive pre-financing

SYDNEY, Sept. 16, 2026 (GLOBE NEWSWIRE) — Cambium Bio Limited (ASX: CMB) (“Cambium Bio” or the “Company”), a clinical-stage regenerative medicine company developing biologic therapies for ophthalmology, today announced that it has secured an A$10.85 million funding package to initiate its pivotal Phase 3 trial of Elate Ocular® in moderate to severe dry eye disease (“DED”). The package comprises A$7.1 million (US$5.0 million) in firm commitments from strategic shareholders through a placement priced at A$0.48 per share, a 4.3% premium to the last closing price, and an A$3.75 million secured facility that pre-finances the Company’s FY2027 Research and Development Tax Incentive refund.

Highlights

  • Strategic capital at a premium. A$7.1 million committed by strategic shareholders, extending a track record of raising capital at a premium.
  • Funding to initiate the pivotal trial. CAMOMILE-2 is a single 475-patient Phase 3 trial that the U.S. Food and Drug Administration (FDA) has confirmed is sufficient to support a Biologics License Application (BLA). Initiation is targeted for the fourth quarter of 2026.
  • A potential first-in-class biologic. Elate Ocular® is a biologic derived from human platelet lysate. To the Company’s knowledge, no biologic therapy has been approved for the treatment of dry eye disease, and Elate Ocular® has the potential to be the first. The program holds FDA Fast Track designation.
  • Clear path to registration. Topline data from the pivotal trial are targeted for late calendar 2027. Subject to the trial meeting its co-primary sign and symptom endpoints, the Company intends to file a BLA with the FDA in 2028.

Karolis Rosickas, Chief Executive Officer of Cambium Bio, said:

“Our strategic shareholders have once again backed Cambium Bio at a premium to market, and that support now gives us the funding to start the pivotal trial of Elate Ocular®. Dry eye disease still has no approved biologic therapy. With one pivotal trial agreed with the FDA, Fast Track designation and the funding in place to initiate that trial, our path is clear: topline data in late 2027 and a BLA filing in 2028.”

The placement is conditional on shareholder approval at the Company’s 2026 Annual General Meeting. Full details are in the Company’s ASX announcement dated 16 September 2026 at www.asx.com.au.

About Cambium Bio Limited

Cambium Bio Limited (ASX: CMB) is a Sydney-based clinical-stage regenerative medicine company developing biologics for ophthalmology and tissue repair from its proprietary human platelet lysate technology. Its lead product candidate, Elate Ocular®, is being developed for moderate to severe dry eye disease.

Contact

Karolis Rosickas, Chief Executive Officer
info@cambium.bio

IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX) today announced the pricing of an underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per share, which equals the public offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. The gross proceeds from this offering are expected to be $150.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Beta Bionics. The offering is expected to close on or about September 17, 2026, subject to customary closing conditions. In addition, Beta Bionics has granted the underwriters for the offering a 30-day option to purchase up to 1,304,348 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Beta Bionics expects to use the net proceeds from this offering for general corporate purposes, which may include costs associated with the commercialization of MintTM, including expansion of Beta Bionics’ manufacturing facilities, research and development and clinical development, investment in product enhancements, potential strategic opportunities and working capital and operating expenses.

J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners are acting as the joint book-running managers for the offering.

The shares of common stock and pre-funded warrants described above are being offered by Beta Bionics pursuant to a shelf registration statement on Form S-3 that was filed by Beta Bionics with the Securities and Exchange Commission (SEC) on February 24, 2026 and automatically became effective upon filing. A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or from Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com; or from Wells Fargo Securities, LLC, Attention: Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, by telephone at 800-645-3751 (option #5), by email at WFScustomerservice@wellsfargo.com; or from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD.

Cautionary Note on Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as “may,” “expects,” “goal,” “intend,” “will,” “would,” “subject to” or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding Beta Bionics’ expectations with respect to the completion, timing and size of the public offering, and the use of proceeds from the offering. For such statements, Beta Bionics claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Beta Bionics’ expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, changes in market conditions, the risk that the offering will not be consummated on the timing contemplated or otherwise, and the satisfaction of customary closing conditions related to the offering, as well as the risks and uncertainties discussed in the preliminary prospectus supplement for the offering and other risks and uncertainties disclosed in Beta Bionics’ filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as updated by its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 29, 2026, and other filings that Beta Bionics may make from time to time with the SEC. These forward-looking statements represent Beta Bionics’ judgment as of the time of this release. Beta Bionics disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com

Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com

Phoenix, AZ, Sept. 15, 2026 (GLOBE NEWSWIRE) — InnSuites Hospitality Trust (NYSE American: IHT) announced record Fiscal 2027 (February 1, 2026 through January 31, 2027) First Fiscal Half Total Revenues of $4,099,593.

Consolidated Net Income before non-cash items primarily consisting of depreciation was $120,280 for the 2027 First Fiscal Half ended July 31, 2026. This represents an increase of $178,057 over the prior year.

Combined Hotel Occupancy was 83.42% for the First Fiscal Half of Fiscal Year 2027, which was approximately a 3.04% increase from the prior First Fiscal Half, while the Revenue Per Available Room and Suites (REVPAR), modestly increased from $78.48 to $79.66 over this same period.

IHT hotel operations were strong in the 2026 Fiscal Year ended January 31, 2026, and contributed to a steady First Half in the current 2027 Fiscal Year. Combined Hotel August Revenue for both hotels was $513,145, which led to total Hotel Revenue of approximately $4.5 million for the First Seven Fiscal Months of Fiscal 2027, a combined record. IHT’s strong hotel operating results are reflected in three of the five most recent Fiscal Years profitable, even after accounting for substantial depreciation and other non-cash expenses. These are positive signs for InnSuites, as progress remains strong, despite 2026 Travel Industry uncertainty.

On August 19, 2026, the Trust increased its shareholders’ equity by $3 million and reduced debt by $3 million.

InnSuites Hospitality Trust continues to explore diversification opportunities and opportunities to increase Equity, potentially including a merger or reverse merger, which is of high interest.

The continued growing demand for electricity from data centers plus the influx of electric vehicles, as well as projected growing needs for artificial intelligence, increased demand for electricity over the next five years is projected to approximately double, and bodes well for the IHT investment in UniGen Power, Inc. This product is a potentially power industry disruptive economical, relatively clean energy, cost effective electric generation innovation. Even though it is high risk, UniGen offers IHT high upside potential.

On February 20, 2026, James Wirth, IHT President, was elected Chairman, CEO, and President of UniGen, while Marc Berg, IHT EVP, was elected as Vice Chairman, EVP, and Secretary/Treasurer of UniGen, with plans to rejuvenate the UniGen progress, while also holding all the UniGen Board seats.

On March 5, 2025, REF, an investment entity owned by the chairman and family of IHT majority IHT shareholder, purchased IBC Hotels, LLC, and hired RRF LLLP, the management company subsidiary of InnSuites Hospitality Trust (IHT), to manage the rebirth of IBC. In the process, RRF LLLP, obtained a five-year option to purchase, at cost, IBC Hotels, LLC. This option is believed to provide IHT a valuable upside opportunity, if successful, to profit from the revitalization of InnDependent Boutique Collection (IBC Hotels).

IHT management believes that due to real estate held on the books of IHT at book values significantly below current market value, due to clean energy diversification high profit potential ahead, IBC independent hotel services prospects, a potential merger or reverse merger future, plus improving hospitality profitability before non-cash depreciation and other non-cash items, along with the recent increase of IHT equity of $3 million, the IHT future looks bright.

IHT future plans include continuation of its uninterrupted annual dividend, beginning in its inception in 1971, with the next dividend tentatively scheduled for February 15, 2027, at the beginning of the 2028 Fiscal Year.

Management believes that the Trust’s hotel operating results, real estate assets, capitalization initiatives, and strategic alternatives provide a positive basis for future of the Trust. There can be no assurance that any of these initiatives will be successful, that the Trust will complete any equity-enhancing transaction, or that the Trust will regain or maintain compliance with NYSE American continued listing standards.

For more information, visit www.innsuitestrust.com and www.innsuites.com.

Forward-Looking Statements

With the exception of historical information, matters discussed in this news release may include “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements include, without limitation, statements regarding the Trust’s intended submission of a compliance plan to NYSE American; the Trust’s ability to regain compliance with NYSE American continued listing standards; potential actions to increase stockholders’ equity; potential conversion of related-party indebtedness into IHT equity; potential capital-raising, capitalization restructuring, or strategic transactions; potential merger or reverse merger opportunities; operating initiatives; hotel operating trends; future annual dividends; diversification opportunities; opportunities involving IBC Hotels, LLC and UniGen Power, Inc.; and expected costs, benefits, timing, or results of any of the foregoing.

Actual developments, business decisions, results, and future actions may differ materially from those expressed or implied by such forward-looking statements. Important factors, among others, that could cause actual results and future actions to differ materially include: NYSE American’s review of the Trust’s compliance plan; the Trust’s ability to complete any equity-enhancing transaction; the Trust’s ability to regain and maintain compliance with NYSE American continued listing standards; the availability, terms, and timing of financing or capitalization alternatives; the outcome of any related-party transaction review; accounting treatment of proposed transactions; required board, committee, NYSE American, shareholder, or other approvals; market conditions; hotel operating results; seasonality; liquidity needs; the outcome of any merger or reverse merger or strategic transaction discussions; the timing and success of potential diversification initiatives; risks relating to IBC Hotels, LLC and UniGen Power, Inc.; economic effects of international conflicts, tariffs, inflation, interest rates, travel industry conditions, and other macroeconomic factors; and the risks described in the Trust’s filings with the Securities and Exchange Commission.

The Trust undertakes no obligation to update any forward-looking statement contained in this news release to reflect events or circumstances after the date of this news release, except as required by applicable law.

FOR FURTHER INFORMATION:

Marc Berg, Executive Vice President
602-944-1500
email: mberg@innsuites.com

INNSUITES HOSPITALITY CENTRE
1730 E. NORTHERN AVENUE, #122
Phoenix, Arizona 85020
Phone: 602-944-1500

NEW YORK and HONG KONG, Sept. 15, 2026 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Apollo-managed funds, affiliates, and other long-term investors provided a $585 million financing to The Executive Centre (“TEC”), one of Asia’s leading providers of premium flexible office space, with more than 30 years of operating experience and a portfolio of over 260 centres across 38 cities in 15 markets across APAC and the Middle East. Proceeds will be primarily used to refinance existing debt and positions TEC for further expansion to meet sustained demand for premium flexible office spaces in the region.

“We are excited to deliver a tailored solution to The Executive Centre that supports their business needs and long-term strategic objectives,” said Celia Yan, Partner and Co-Head of APAC Credit & Hybrid at Apollo. “Bespoke hybrid solutions require deep cross-collaboration and the ability to understand both investors and management teams alike, and we are pleased to be TEC’s partner of choice for this transaction.”

“TEC has spent three decades building a trusted platform for multinational clients who need the flexibility to scale across Asia. Apollo’s ability to deliver a solution signals confidence and addresses both our refinancing objectives and growth ambitions, reflecting the long-term, partnership-driven approach we were looking for,” a spokesperson for The Executive Centre stated.

The investment builds on Apollo’s track record of hybrid capital solutions in Asia including transactions with JSW Cement, Global Schools Group, Hero FinCorp, HMI/PanAsia Health, Molycop and Charles Monat Associates.

A&O Shearman acted as legal counsel to Apollo. Clifford Chance acted as legal counsel and Rippledot Capital as financial advisor to The Executive Centre.

About Apollo
Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative, and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees, and the communities we impact, to expand opportunity and achieve positive outcomes. As of June 30, 2026, Apollo had approximately $1.05 trillion of assets under management. To learn more, please visit www.apollo.com.

Contacts

Noah Gunn
Global Head of Investor Relations
+1 (212) 822-0540
IR@apollo.com

Joanna Rose
Global Head of Corporate Communications
+1 (212) 822-0491
Communications@apollo.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.